Sign up for free to view insider transactions by individual.
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows
PTC Therapeutics Board Authorizes $500M Share Repurchase Program
Citigroup Maintains Buy on PTC Therapeutics, Raises Price Target to $109
PTC Therapeutics to Participate in Upcoming Investor Conferences
PTC Therapeutics (PTCT) Stock Slides As Q3 Results Return To Loss
PTC Therapeutics (PTCT) Lifts Guidance As Fair Value Stays In Focus
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TD Cowen Maintains Buy on PTC Therapeutics, Raises Price Target to $95
PTC Therapeutics (PTCT) Q3 2026 Earnings Call Transcript
RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $77
Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $112
PTC Therapeutics, Inc. Q3 2026 Earnings Call Summary
PTC Therapeutics Q3 Earnings Call Highlights
PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
PTC Therapeutics (NASDAQ:PTCT) Q3 Beat and Raised Guidance Meet Cautious After-Hours Reaction
PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
PTC Therapeutics: Q3 Earnings Snapshot
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
PTC Therapeutics Q3 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.